Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Texts and trackers: a new way to boost vitamin use in pregnancy?

NCT ID NCT07555093

First seen Apr 30, 2026 · Last updated Jun 19, 2026 · Updated 8 times

Summary

This study will enroll about 10,000 pregnant women in Lombok, Indonesia, to see if digital tools like WhatsApp reminders and a call center can help them stick to taking daily multiple micronutrient supplements. It will also compare two types of packaging—bottles vs. blister packs—to see which one works better. Participants will be followed through pregnancy and up to six weeks after birth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHERENCE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Summit Institute for Development

    Mataram, West Nusa Tenggara, 83239, Indonesia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

multiple micronutrient supplementation (MMS)

What this could lead to

If successful, this could show that simple digital tools and better packaging help more pregnant women take their daily supplements, potentially improving health for mothers and babies.

What could go wrong

This is an early implementation study, not a test of the supplement itself. Results may not apply to other regions, and adherence may still be low despite digital support.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.